Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Comment by lscfaon Jan 07, 2023 3:27pm
338 Views
Post# 35208986

RE:Raymond James expects 30mil equity raise - dilution coming?

RE:Raymond James expects 30mil equity raise - dilution coming?
besttobe wrote: VALUATION We update our models (Ex. 1) in which we conservatively assume a 3% organic growth rate, and no additional M&A through 2023 as QIPT’s management team—whom we’ve come to appreciate as very strong operators (yet another reason for right-sizing of QIPT’s valuation multiple)— ensures the acquisition of Great Elm is neatly and fully integrated. Also, while management indicated that the carrying cost of the $73 mln debt is very manageable given QIPT’s ~2.0 debt/ equity ratio, we conservatively assume a near-term $30 mln equity raise @ $9/sh deriving a proforma FD sh. count of 42.5 mln. As such, we roll forward our valuation of QIPT to a blended 10x 2023E EV/EBITDA and 8x 2024E EV/EBITDA multiple (corrected from previous inaccurate 12x and 10x resp.)
lame bashing.  New equity at $9 US for accretive deals is not dilutive.

<< Previous
Bullboard Posts
Next >>